Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
bb2121 is a chimeric antigen receptor T cell specific to B cell maturation antigen (BCMA), which could potentially result in decreased volume of BCMA expressing tumor cells (Journal for ImmunoTherapy of Cancer 2015 3(Suppl 2):P124).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Idecabtagene Vicleucel||Abecma||Ide-cel|bb2121||Abecma (idecabtagene vicleucel) is a chimeric antigen receptor T cell specific to B cell maturation antigen (BCMA), which could potentially result in decreased volume of BCMA expressing tumor cells (PMID: 32707894, PMID: 33626253). Abecma (idecabtagene vicleucel) is FDA approved for use in adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||multiple myeloma||not applicable||bb2121||FDA approved||Actionable||In a Phase II trial (KarMMa) that supported FDA approval, Abecma (idecabtagene vicleucel) treatment resulted in an objective response rate of 73% (94/128) and a complete response rate of 33% (42/128) in patients with relapsed or refractory multiple myeloma, with a median duration of response of 10.6 months and a median progression-free survival of 8.8 months (PMID: 33626253; NCT03361748).||33626253 detail...|
|Unknown unknown||multiple myeloma||not applicable||bb2121||Phase I||Actionable||In a Phase I trial, Abecma (idecabtagene vicleucel) treatment in multiple myeloma patients resulted in an overall response rate of 78% (7/9), including two patients who experienced complete remission, four patients who achieved partial response, and one patient who experienced stable disease (EORTC-NCI-AACR Symposium, 2016, Abstract #14).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03361748||Phase II||bb2121||Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma (KarMMa) (bb2121)||Active, not recruiting||USA | CAN||6|
|NCT03651128||Phase III||Bortezomib + Daratumumab + Dexamethasone bb2121 Dexamethasone + Ixazomib + Lenalidomide Daratumumab + Dexamethasone + Pomalidomide||Efficacy and Safety Study of bb2121 Versus Standard Triplet Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)||Recruiting||USA | CAN||9|
|NCT02658929||Phase I||bb2121||Study of bb2121 in Multiple Myeloma||Active, not recruiting||USA||0|
|NCT03601078||Phase II||bb2121||An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma Having Progressed Within One Year of Initial Treatment (KarMMa-2)||Recruiting||USA||5|